Roger Melton

Roger Melton has served as Inotiv’s director of drug metabolism and pharmacokinetics (DMPK) since 2019, and brings over 25 years of experience in drug discovery. In this role, he leads the discovery bioanalytical organization, a team of pharmacokineticists, and the biotransformation group within DMPK in support for preclinical studies and human clinical trials. Roger provides strategic direction, creates, implements, and maintains routine and customized processes that guarantee high-quality data and reports for our clients. In addition, he serves as a primary contact between the facility, study directors, and clients.

Melton joined Seventh Wave Laboratories (now Inotiv) in 2008 as a pharmacokineticist and began building a diversified DMPK organization with the experience from his career at Pharmacia/Pfizer, becoming associate director of DMPK in 2016 until his promotion to his current position. He brings Inotiv a diverse background in molecular biology, dating back to his experience at Washington University Medical School, as well as strong industry experience as a DMPK scientist at Pharmacia and senior scientist at Pfizer.

Back to Team